% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{DomnguezMendoza:904543,
author = {Domínguez-Mendoza, Elix Alberto and Galván-Ciprés,
Yelzyn and Martínez-Miranda, Josué and Miranda-González,
Cristian and Colín-Lozano, Blanca and Hernández-Núñez,
Emanuel and Hernández-Bolio, Gloria I. and
Palomino-Hernández, Oscar and Navarrete-Vazquez, Gabriel},
title = {{D}esign, {S}ynthesis, and {I}n {S}ilico {M}ultitarget
{P}harmacological {S}imulations of {A}cid {B}ioisosteres
with a {V}alidated {I}n {V}ivo {A}ntihyperglycemic {E}ffect},
journal = {Molecules},
volume = {26},
number = {4},
issn = {1420-3049},
address = {Basel},
publisher = {MDPI},
reportid = {FZJ-2021-06113},
pages = {799 -},
year = {2021},
abstract = {Substituted phenylacetic (1–3), phenylpropanoic (4–6),
and benzylidenethiazolidine-2,4-dione (7–9) derivatives
were designed according to a multitarget unified
pharmacophore pattern that has shown robust antidiabetic
activity. This bioactivity is due to the simultaneous
polypharmacological stimulation of receptors PPARα, PPARγ,
and GPR40 and the enzyme inhibition of aldose reductase (AR)
and protein tyrosine phosphatase 1B (PTP-1B). The nine
compounds share the same four pharmacophore elements: an
acid moiety, an aromatic ring, a bulky hydrophobic group,
and a flexible linker between the latter two elements.
Addition and substitution reactions were performed to obtain
molecules at moderated yields. In silico pharmacological
consensus analysis (PHACA) was conducted to determine their
possible modes of action, protein affinities, toxicological
activities, and drug-like properties. The results were
combined with in vivo assays to evaluate the ability of
these compounds to decrease glucose levels in diabetic mice
at a 100 mg/kg single dose. Compounds 6 (a phenylpropanoic
acid derivative) and 9 (a benzylidenethiazolidine-2,4-dione
derivative) ameliorated the hyperglycemic peak in a
statically significant manner in a mouse model of type 2
diabetes. Finally, molecular dynamics simulations were
executed on the top performing compounds to shed light on
their mechanism of action. The simulations showed the
flexible nature of the binding pocket of AR, and showed that
both compounds remained bound during the simulation time,
although not sharing the same binding mode. In conclusion,
we designed nine acid bioisosteres with robust in vivo
antihyperglycemic activity that were predicted to have
favorable pharmacokinetic and toxicological profiles.
Together, these findings provide evidence that supports the
molecular design we employed, where the unified
pharmacophores possess a strong antidiabetic action due to
their multitarget activation},
cin = {IAS-5 / INM-9},
ddc = {540},
cid = {I:(DE-Juel1)IAS-5-20120330 / I:(DE-Juel1)INM-9-20140121},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {33557136},
UT = {WOS:000624192300001},
doi = {10.3390/molecules26040799},
url = {https://juser.fz-juelich.de/record/904543},
}